Functional Medical Imaging Quantization in Prostate Cancer (QUIP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03376360|
Recruitment Status : Completed
First Posted : December 18, 2017
Last Update Posted : August 15, 2018
Prostate cancer is the most common cancer in men over 50 years old and the third leading cause of cancer death. Because of the variety of prostate cancers, different treatments exist.
Several criteria guide this management in daily practice: PSA level; TNM stage (digital rectal examination, trans-rectal ultrasound and classical visual imaging) and pathological differentiation with the Gleason score, to which can be added other prognostic criteria: growth and doubling time of the serum PSA, number of positive biopsies and percentage of cancer lesions by biopsy.
Functional imaging by PET and MRI is increasingly used in daily clinical practice to characterize prostate cancer, either during initial discovery or during recurrence. In this context, it is the qualitative visual analysis that is mainly used. Quantitative image analysis could add new criteria to guide patient management.
Consequently, the objective of this study were:
- Optimization of 18F-choline PET/CT Acquisition in Prostate Cancer
- Comparison the quantitative parameters obtained by 18F-Choline PET / CT and both perfusion MRI and histological parameters.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||61 participants|
|Official Title:||Optimization of 18F-choline PET/CT Acquisition in Prostate Cancer: Preliminary Results Concerning the Length of the Acquisition|
|Actual Study Start Date :||October 1, 2015|
|Actual Primary Completion Date :||May 1, 2017|
|Actual Study Completion Date :||May 1, 2017|
- correlation between Gleason score and dynamic parameters on PET and MRI [ Time Frame: when anatomopathological report is available, an average of 3 months after the PET/CT ]study the potential correlation between dynamic parameters on PET and MRI
- reconstructions on 18F-choline PET [ Time Frame: when all 18F-choline PET are performed, an average of 6 months ]determine the mean influx from each reconstruction which is the closest to the objective value
- best "fitting" on PET and MRI [ Time Frame: when all MRI are performed, an average of 6 months ]the Akaike Criteria Information was chose to choose the best fit
- comparison between data (PSA, TNM stage, EFS and OS) [ Time Frame: 01/05/2017 ]comparison between data (PSA, TNM stage, EFS and OS)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03376360
|CHRU de Brest|
|Brest, France, 29609|